A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA).

Trial Profile

A 28 Week, Treatment Randomized, Double -Blind, Placebo-controlled Study of the Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA).

Completed
Phase of Trial: Phase II

Latest Information Update: 23 May 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms KIA
  • Most Recent Events

    • 15 May 2017 Status changed from active, no longer recruiting to completed.
    • 06 Mar 2017 Results of effects of imatinib on airway mast cells presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 13 Sep 2012 Planned End Date changed from 1 Apr 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top